Investor webinar scheduled for August 26, 2026 at 11:00 a.m. EDT

JERUSALEM, Aug. 24, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company combining innovative therapeutic development with a revenue-generating contract development and manufacturing organization ("CDMO"), today provided a corporate update and reported financial results for the six months ended June 30, 2026.

Corporate Highlights

   -- Committed Customer Orders1 reached approximately $3.1 million as of 
      August 16, 2026, of which approximately $2.1 million had been invoiced. 
 
   -- The Company is progressing an expanded clinical manufacturing and CMC 
      program for a U.S.-based biopharmaceutical company building on an 
      existing contractual relationship and prior work performed through the 
      customer's affiliate. 
 
   -- Approximately $650 thousand in cash payments and advances have been 
      received in connection with the expanded U.S. program, and substantive 
      activities are underway while the definitive agreement covering the 
      broader scope and commercial terms remains under negotiation. 
 
   -- The expanded program is intended to support an investigational drug 
      product toward U.S. IND submission and Phase III clinical development. 
 
   -- The Company continues to pursue approximately $5 million in CDMO revenues 
      for 2026 

First Half 2026 Financial Results

   -- Revenues increased to $949 thousand, compared with $773 thousand for the 
      six months ended June 30, 2025. The increase was primarily attributable 
      to the inclusion of revenues generated by the acquired Yavne operations 
      from the acquisition date. Revenue recognized during the period reflects 
      only the portion of customer engagements for which the applicable 
      services had been performed and revenue recognition criteria satisfied 
      through June 30, 2026, and does not reflect the full value of signed 
      customer work orders extending beyond the reporting period. 
 
   -- Cost of revenues increased to $3.3 million, compared to approximately 
      $2.0 million for the six months ended June 30, 2025, primarily reflecting 
      the expanded cost base of our CDMO business following the acquisition and 
      consolidation of the Yavne operations, including additional personnel, 
      facility, depreciation and other manufacturing-related costs. 
 
   -- Gross loss was approximately $2.4 million, compared with approximately 
      $1.3 million in the prior-year period, reflecting the expanded operating 
      cost base of the Company's CDMO platform while facility utilization 
      continues to increase. 
 
   -- Research and development expenses decreased to approximately $0.8 million, 
      compared to approximately $1.2 million for the six months ended June 30, 
      2025 primarily reflecting a lower level of research and development 
      expenditures during the period and the continuing allocation of resources 
      toward our CDMO activities, partially offset by expenditures associated 
      with our current therapeutic development programs, including the PinCell 
      arrangement and NanoAb activities. 
 
   -- Marketing, general and administrative expenses increased to approximately 
      $1.4 million, compared to approximately $1.3 million for the six months 
      ended June 30, 2025 reflecting, among other things, the expanded 
      corporate and administrative requirements associated with the acquisition 
      and integration of the Yavne operations and operation of the enlarged 
      group structure. 
 
   -- Operating loss was approximately $4.6 million, compared with 
      approximately $3.8 million for the first half of 2025. 
 
   -- Net income was approximately $1.6 million, compared with a net loss of 
      approximately $4.1 million in the prior-year period, primarily reflecting 
      an approximately $6.4 million bargain purchase gain associated with the 
      acquisition of Recipharm Israel. The bargain purchase gain does not 
      represent operating revenue or operating cash flow. 
 
   -- Net cash used in operating activities was approximately $3.9 million, 
      compared with approximately $2.6 million in the first half of 2025. 
 
   -- Cash, cash equivalents and restricted cash totaled approximately $2.9 
      million as of June 30, 2026, and shareholders' equity was approximately 
      $11.7 million. At the closing of the acquisition, Recipharm Israel held 
      approximately EUR2.0 million in cash, alongside funds for certain 
      pre-closing expenses and liabilities. The acquired cash contributed to 
      the Company's post-acquisition liquidity position. 

CEO Commentary

Amir Reichman, Chief Executive Officer of Scinai, commented:

"The first half of 2026 was focused on expanding and integrating our CDMO platform. As we move through the second half of the year, our focus is increasingly on commercial execution, increasing facility utilization and converting the capabilities we have built into revenue.

We are particularly encouraged by the expansion of an existing U.S. customer engagement from an initial feasibility and cGMP-readiness project into a broader proposed clinical manufacturing and CMC program designed to support a planned U.S. IND submission and Phase III clinical development with potential future expansion into commercial manufacturing. We have already received approximately $650 thousand in cash payments and advances and commenced substantive activities while the definitive agreement covering the expanded scope and commercial terms is being negotiated.

We believe this opportunity is significant not only because of its potential financial contribution, but also because successful execution would demonstrate our ability to support an advanced U.S. clinical development program through CMC development, manufacturing readiness and clinical cGMP manufacturing.

Our priorities for the remainder of 2026 are clear: execute our existing customer programs, convert our commercial pipeline into revenue, increase utilization of our Jerusalem and Yavne facilities, progress this significant U.S. opportunity and continue advancing our therapeutic programs with disciplined capital allocation."

R&D Update

Scinai continues to pursue a capital-efficient development strategy focused on PC111 and its NanoAbs platform.

For PC111, the Company is evaluating its funding and development path, including potential participation in a future Polish FENG funding round, and is in discussions with PinCell regarding a potential extension of the existing option arrangement.

For the NanoAbs platform, Scinai continues to prioritize its systemic IL-17 bispecific antibody program and its research collaboration and license arrangements with the Max Planck Society and University Medical Center Göttingen.

Investor Webinar

Scinai will provide additional perspective on the expanded U.S. clinical manufacturing opportunity, its broader CDMO commercial pipeline, progress across its R&D programs, including PC111 and the NanoAbs platform, and its strategic priorities for the remainder of 2026 during an investor webinar on August 26, 2026 at 11:00 a.m. EDT.

Investors and other interested parties are invited to register here: LINK

The webinar will include a management presentation followed by a question-and-answer session.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company focused on the development of innovative immunology therapies and the operation of a contract development and manufacturing organization.

The Company is advancing therapeutic programs based on technology licensed from the Max Planck Society and pursuant to its option arrangement with PinCell S.r.l.

Scinai also owns Scinai Biopharma Services Ltd., a CDMO providing development and manufacturing services to biotechnology and pharmaceutical companies through facilities in Jerusalem and Yavne, Israel.

For more information, please visit www.scinai.com.

Company Contacts

Business Development | +972 8 930 2529 | bd@scinai.com

Investor Relations, Allele Capital Partners | +1 978 857 5075 | aeriksen@allelecapital.com

(1) Committed Customer Orders

   -- We define "committed customer orders" as the aggregate value of signed 
      customer purchase orders for specified CDMO services under existing 
      contractual arrangements, whether or not such amounts have been invoiced. 
      Management uses committed customer orders as an indicator of committed 
      commercial activity and anticipated CDMO utilization, and we believe this 
      measure provides investors with useful information regarding the value of 
      customer-authorized projects under signed purchase orders. 
 
   -- Committed customer orders are presented for supplemental informational 
      purposes only and are not intended as a substitute for GAAP financial 
      measures. Although customer purchase orders are generally non-cancellable, 
      committed customer orders should not be interpreted as an indication of 
      future revenue or cash receipts. The timing and amount of revenue 
      recognition and cash payments depend on various factors, including 
      performance of the applicable services, achievement of contractual 
      milestones and satisfaction of the relevant accounting criteria. Projects 
      may also be delayed, modified or remain open for extended periods. 

Forward-Looking Statements